Showing results (1801-1810 of 1,838) with videos related to

Sort By:
Pageof 184
Physical Review Letters|March 10, 2012
Femtosecond dynamics of the collinear-to-spiral antiferromagnetic phase transition in CuOS L Johnson, R A de Souza, U Staub, et al.
Nature Communications|June 9, 2015
Direct characterization of photoinduced lattice dynamics in BaFe2As2S Gerber, K W Kim, Y Zhang, et al.
Hypertension (Dallas, Tex. : 1979)|November 29, 2023
Genomic Selection Signals in Andean Highlanders Reveal Adaptive Placental Metabolic Phenotypes That Are Disrupted in PreeclampsiaKatie A O'Brien, Wanjun Gu, Julie A Houck, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Reconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9Negar Khazan, Cameron Wa Snyder, Nicole Dawney, et al.
Journal of Medicinal Chemistry|November 5, 1997
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastaseC A Veale, P R Bernstein, C M Bohnert, et al.
Elife|July 1, 2015
The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictusMoritz U G Kraemer, Marianne E Sinka, Kirsten A Duda, et al.
Urology|June 7, 2000
Survey of neuromuscular injuries to the patient and surgeon during urologic laparoscopic surgeryJ S Wolf, R Marcovich, I S Gill, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Normal Risk Ovarian Screening Study: 21-Year UpdateChae Young Han, Karen H Lu, Gwen Corrigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III TrialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Pageof 184